JP2003183146A - Skin care preparation for external use - Google Patents

Skin care preparation for external use

Info

Publication number
JP2003183146A
JP2003183146A JP2001382687A JP2001382687A JP2003183146A JP 2003183146 A JP2003183146 A JP 2003183146A JP 2001382687 A JP2001382687 A JP 2001382687A JP 2001382687 A JP2001382687 A JP 2001382687A JP 2003183146 A JP2003183146 A JP 2003183146A
Authority
JP
Japan
Prior art keywords
skin
present
skin care
external use
care preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001382687A
Other languages
Japanese (ja)
Other versions
JP3574107B2 (en
Inventor
Toshio Hikima
俊雄 引間
Minoru Sasaki
稔 佐々木
Sachiyo Hirotsu
祥代 廣津
Yasuto Takahashi
慶人 高橋
Ayumi Kusaka
あゆみ 日下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanebo Ltd
Original Assignee
Kanebo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanebo Ltd filed Critical Kanebo Ltd
Priority to JP2001382687A priority Critical patent/JP3574107B2/en
Publication of JP2003183146A publication Critical patent/JP2003183146A/en
Application granted granted Critical
Publication of JP3574107B2 publication Critical patent/JP3574107B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a skin care preparation for external use possessing an excellent skin inflammation-preventing effect and whitening effect. <P>SOLUTION: This skin care preparation for external use contains extracts obtained from Saint John's wort (Hypericum erectum Thunb.) and olive (Olea europaea Linne) foliage. The skin care preparation for external use further contains at least one or more than two kinds selected from the group consisting of glycyrrhizinic acid and its derivatives, glycyrrhetinic acid and its derivatives and allantoin. <P>COPYRIGHT: (C)2003,JPO

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、優れた皮膚炎症防
止効果、美白効果を有する皮膚外用剤に関するものであ
る。
TECHNICAL FIELD The present invention relates to an external preparation for skin having an excellent effect of preventing skin inflammation and a whitening effect.

【0002】[0002]

【従来の技術】従来、日焼けによる皮膚の炎症を抑える
ために、カラミン等の抗炎症効果を有する薬剤が、また
日焼け後の色素沈着を抑えるためには、アスコルビン
酸、グルタチオン等の美白効果を有する薬剤が皮膚外用
剤の成分として用いられてきた。
2. Description of the Related Art Conventionally, agents having an anti-inflammatory effect such as calamine have been used to suppress skin inflammation due to sunburn, and whitening effects such as ascorbic acid and glutathione have been used to suppress pigmentation after sunburn. Drugs have been used as a component of topical skin preparations.

【0003】[0003]

【発明が解決しようとする課題】しかしながら、これら
の薬剤を含有する皮膚外用剤は、抗炎症効果、美白効果
が弱く、未だ充分満足すべきものではなかった。
However, external preparations for skin containing these agents have weak anti-inflammatory effects and whitening effects, and have not been sufficiently satisfactory.

【0004】[0004]

【課題を解決するための手段】上記実情に鑑み、本発明
者等は、鋭意研究を行った結果、オトギリソウから得ら
れる抽出物と、オリーブの枝葉部から得られる抽出物と
を配合することにより、前記問題点を解決し、日焼けに
よる皮膚の炎症及び日焼け後の色素沈着を抑える効果が
相乗的に改善した皮膚外用剤が得られることを見出し、
本発明を完成した。
In view of the above-mentioned circumstances, the present inventors have conducted diligent research, and as a result, by combining an extract obtained from Hypericum perforatum and an extract obtained from the branches and leaves of olives, It was found that a skin external preparation having the above-mentioned problems solved and synergistically improved in the effect of suppressing skin inflammation due to sunburn and pigmentation after sunburn is obtained,
The present invention has been completed.

【0005】すなわち本発明の請求項1は、オトギリソ
ウから得られる抽出物、及びオリーブの枝葉部から得ら
れる抽出物を含有することを特徴とする皮膚外用剤であ
る。
That is, claim 1 of the present invention is a skin external preparation characterized by containing an extract obtained from Hypericum perforatum and an extract obtained from the branches and leaves of olives.

【0006】また本発明の請求項2は、更にグリチルリ
チン酸及びその誘導体、グリチルレチン酸及びその誘導
体、アラントインからなる群より選択される1種又は2
種以上を含有することを特徴とする請求項1記載の皮膚
外用剤である。
Further, claim 2 of the present invention further comprises one or two selected from the group consisting of glycyrrhizic acid and its derivatives, glycyrrhetinic acid and its derivatives, and allantoin.
The external preparation for skin according to claim 1, which contains one or more kinds.

【0007】[0007]

【発明の実施の形態】以下、本発明の実施の形態を詳説
する。
BEST MODE FOR CARRYING OUT THE INVENTION Embodiments of the present invention will be described in detail below.

【0008】本発明で使用する「オトギリソウ」とは、
オトギリソウ科(Guttiferae)、オトギリソウ属(Hype
ricum)の植物:オトギリソウ(Hypericum erectum Thu
nb.)、セイヨウオトギリソウ(Hypericum perforatum
L.)、コゴメバオトギリソウ(Hypericum perforatum L.
var angustifoliom D.C)を指し、本発明においては、
その全草及び/又は花が用いられる。
"Hypericum perforatum" used in the present invention means
Hypericumaceae (Guttiferae), Hypericum (Hype
ricum) plant: Hypericum erectum Thu
nb.), Hypericum perforatum (Hypericum perforatum)
L.), Hypericum perforatum L.
var angustifoliom DC), and in the present invention,
The whole plant and / or flowers are used.

【0009】本発明で使用する「オリーブ」とは、モク
セイ科(Oleaceae)、オリーブ属(Olea)の植物:オリーブ
(Olea europaea Linne)を指し、本発明においては、そ
の枝及び/又は葉が用いられる。またその他の同属種、
例えば、オレア・ウェルウィトスキイ(O.welwitschi
i)、オレア・パニクラタ(O.paniculata)等を用いるこ
ともできる。
The term "olive" used in the present invention means a plant of the family Oleaceae or genus Olea: olive.
(Olea europaea Linne), and its branches and / or leaves are used in the present invention. Also other congeners,
For example, O.welwitschi
i), Olea paniculata, etc. can also be used.

【0010】本発明に用いられるオトギリソウから得ら
れる抽出物と、オリーブの枝葉部から得られる抽出物の
調製法は特に限定されないが、例えば種々の適当な溶媒
を用いて室温〜加温下で抽出される。抽出溶媒として
は、例えば水;メチルアルコール、エチルアルコール等
の低級一価アルコール;グリセリン、プロピレングリコ
ール、1,3−ブチレングリコール等の液状多価アルコ
ール;酢酸エチル等の低級アルキルエステル;ベンゼ
ン、ヘキサン等の炭化水素;ジエチルエーテル等のエー
テル類等の1種又は2種以上を用いることができるが、
特に水、エチルアルコール、グリセリン、1,3−ブチ
レングリコールの1種又は2種以上の混合溶媒が好まし
い。また抽出条件としては、オトギリソウ、オリーブの
枝葉部に対し容量比で1〜1000倍量、特に5〜10
0倍量の溶媒を用い、4℃以上、特に15〜30℃の温
度で1時間以上、特に1〜3日間行うのが好ましい。
The method for preparing the extract obtained from Hypericum perforatum used in the present invention and the extract obtained from the branches and leaves of olives are not particularly limited. For example, extraction is carried out at room temperature to under heating with various suitable solvents. To be done. Examples of the extraction solvent include water; lower monohydric alcohols such as methyl alcohol and ethyl alcohol; liquid polyhydric alcohols such as glycerin, propylene glycol and 1,3-butylene glycol; lower alkyl esters such as ethyl acetate; benzene and hexane. Hydrocarbons; one or more ethers such as diethyl ether can be used,
Particularly, water, ethyl alcohol, glycerin, and a mixed solvent of one or more kinds of 1,3-butylene glycol are preferable. The extraction conditions are 1 to 1000 times the volume of the branches and leaves of Hypericum and olives, especially 5 to 10 times.
It is preferable to use 0 times the amount of the solvent, and to carry out at a temperature of 4 ° C. or higher, particularly 15 to 30 ° C., for 1 hour or longer, particularly 1 to 3 days.

【0011】以上のような条件で得られるオトギリソ
ウ、オリーブの枝葉部から得られた抽出物は、抽出され
た溶液のまま用いても良いが、更に必要により濃縮、ろ
過等の処理をしたものを用いることができる。
The extract obtained from the branches and leaves of St. John's wort and olives obtained under the above conditions may be used as the extracted solution as it is, but if necessary, it may be subjected to treatment such as concentration and filtration. Can be used.

【0012】本発明に用いられるオトギリソウから得ら
れる抽出物と、オリーブの枝葉部から得られる抽出物の
配合量は、皮膚外用剤の総量を基準とし、乾燥固形分に
換算して0.0001〜10質量%(以下、単に「%」
で示す)が好ましく、特に0.001〜5%の範囲が好
ましい。含有量が0.0001%未満であると本発明の
効果が充分発揮されない場合があり、また10%を超え
て配合しても、それ以上の効果の増大が見られない場合
がある。
The amount of the extract obtained from Hypericum perforatum used in the present invention and the amount of the extract obtained from the branches and leaves of olives are 0.0001-converted to dry solids based on the total amount of the external preparation for skin. 10% by mass (hereinafter, simply "%"
Is preferable, and the range of 0.001 to 5% is particularly preferable. If the content is less than 0.0001%, the effect of the present invention may not be sufficiently exhibited, and if the content exceeds 10%, the effect may not be further increased.

【0013】本発明においては、更にグリチルリチン酸
及びその誘導体、グリチルレチン酸及びその誘導体、ア
ラントインからなる群より選択される1種又は2種以上
を含有することにより、更に効果的な皮膚外用剤を得る
ことができる。
In the present invention, by further containing one or more selected from the group consisting of glycyrrhizic acid and its derivatives, glycyrrhetinic acid and its derivatives, and allantoin, a more effective external preparation for skin is obtained. be able to.

【0014】本発明に用いられるグリチルリチン酸及び
その誘導体としては、グリチルリチン酸、その塩、及び
そのエステル等が挙げられ、具体的にはグリチルリチン
酸、グリチルリチン酸ジカリウム、グリチルリチン酸モ
ノアンモニウム等が例示される。その配合量は、皮膚外
用剤の総量を基準として、0.001〜5%が好まし
く、特に0.01〜1%が好ましい。
Examples of glycyrrhizic acid and its derivative used in the present invention include glycyrrhizic acid, its salt, and its ester. Specific examples thereof include glycyrrhizic acid, dipotassium glycyrrhizinate, and monoammonium glycyrrhizinate. . The blending amount thereof is preferably 0.001 to 5%, and particularly preferably 0.01 to 1%, based on the total amount of the skin external preparation.

【0015】本発明に用いられるグリチルレチン酸及び
その誘導体としては、グリチルレチン酸、その塩、及び
そのエステル等が挙げられ、具体的にはグリチルレチン
酸、グリチルレチン酸ステアレート等が例示される。そ
の配合量は、皮膚外用剤の総量を基準として、0.00
1〜5%が好ましく、特に0.01〜1%が好ましい。
Examples of the glycyrrhetinic acid and its derivative used in the present invention include glycyrrhetinic acid, its salt, and its ester. Specific examples thereof include glycyrrhetinic acid and glycyrrhetinic acid stearate. The blending amount is 0.00 based on the total amount of the skin external preparation.
1 to 5% is preferable, and 0.01 to 1% is particularly preferable.

【0016】本発明に用いられるアラントインの配合量
は、皮膚外用剤の総量を基準として、0.001〜8%
が好ましく、特に0.1〜5%が好ましい。
The amount of allantoin used in the present invention is 0.001 to 8% based on the total amount of the external preparation for skin.
Is preferable, and 0.1 to 5% is particularly preferable.

【0017】更に本発明の皮膚外用剤には、本発明の効
果を損なわない範囲で、前記必須成分の他、通常の皮膚
外用剤に用いられる水性成分、粉体、界面活性剤、油
剤、保湿剤、アルコール類、pH調整剤、防腐剤、色
素、酸化防止剤、紫外線吸収剤、増粘剤、香料、美容成
分等を必要に応じて適宜配合することができる。
Further, the external preparation for skin of the present invention contains, in addition to the above-mentioned essential components, aqueous components, powders, surfactants, oils, moisturizers, which are used in ordinary external preparations for skin, as long as the effects of the present invention are not impaired. Agents, alcohols, pH adjusters, antiseptics, pigments, antioxidants, ultraviolet absorbers, thickeners, fragrances, cosmetic ingredients and the like can be appropriately added as necessary.

【0018】本発明の皮膚外用剤は、必須成分であるオ
トギリソウから得られる抽出物と、オリーブの枝葉部か
ら得られる抽出物を配合し、常法に従って製造すること
ができる。そして乳液、クリーム、化粧水、美容液、ク
レンジング、パック、ファンデーション、洗浄料等の
他、分散液状、軟膏状、顆粒状等の医薬用、医薬部外用
又は化粧用の製剤とすることができる。
The external preparation for skin of the present invention can be produced according to a conventional method by mixing an extract obtained from Hypericum perforatum, which is an essential component, and an extract obtained from the branches and leaves of olives. In addition to emulsions, creams, lotions, beauty essences, cleansing, packs, foundations, detergents, etc., they can be prepared into pharmaceuticals such as dispersion liquids, ointments and granules, quasi-drugs or cosmetics.

【0019】[0019]

【実施例】次に試験例及び実施例を挙げて本発明を更に
詳細に説明するが、本発明はこれらに限定されるもので
はない。
EXAMPLES The present invention will be described in more detail with reference to test examples and examples, but the present invention is not limited thereto.

【0020】尚、オトギリソウから得られる抽出物と、
オリーブの枝葉部から得られる抽出物としては次のもの
を使用した。 ・オトギリソウ抽出物:30vol%エチルアルコール
にて加熱抽出後、ろ過し、減圧濃縮したものを冷所に放
置したもの。乾燥固形分約3% ・オリーブ葉抽出物 :50vol%エチルアルコール
にて還流抽出後、ろ過し、減圧濃縮したものを冷所に放
置したもの。乾燥固形分約2%
An extract obtained from Hypericum perforatum,
The following extracts were used as the extracts obtained from the branches and leaves of olives. Hypericum perforatum extract: A product obtained by heating and extracting with 30 vol% ethyl alcohol, filtering and concentrating under reduced pressure, and leaving it in a cool place. Dry solid content: approx. 3% Olive leaf extract: Extracted by refluxing with 50 vol% ethyl alcohol, filtered, concentrated under reduced pressure and left in a cool place. Dry solid content about 2%

【0021】評価に用いた試験方法は下記の通りであ
る。
The test methods used for evaluation are as follows.

【0022】(1)抗炎症効果試験方法 有色モルモット背部に試料を塗布してその日焼けによる
炎症、色素沈着に対する効果を調べた。
(1) Test Method for Anti-Inflammatory Effect A sample was applied to the back of a colored guinea pig and its effect on inflammation and pigmentation due to sunburn was examined.

【0023】[試験方法]有色モルモット(各群10
匹)の背部を剃毛し、麻酔下紫外線を照射した。紫外線
照射は、東芝社製FL20S・BLBランプとFL20
S・E30ランプを3本ずつ同時に照射し、紫外線量
は、4.8×10-1J/cm2とした。紫外線照射24
時間前と照射直後及び照射12時間後、24時間後にモ
ルモット背部の4箇所に試料を0.2mLずつよくすり
こんだ。但し、照射前には塗布部位を温水で良く洗浄し
た。照射の24時間後に炎症の程度を観察し、7日後
に、色素沈着の程度を観察し、以下の判定基準で判定し
た。
[Test Method] Colored guinea pigs (10 for each group)
The back of each animal was shaved and irradiated with ultraviolet rays under anesthesia. UV irradiation is the FL20S / BLB lamp and FL20 manufactured by Toshiba
Three S / E30 lamps were simultaneously irradiated, and the amount of ultraviolet rays was 4.8 × 10 −1 J / cm 2 . UV irradiation 24
Before the time, immediately after the irradiation, and 12 hours after the irradiation, and 24 hours after the irradiation, 0.2 mL of the sample was rubbed into each of four places on the back of the guinea pig. However, the application site was thoroughly washed with warm water before irradiation. The degree of inflammation was observed 24 hours after the irradiation, and after 7 days, the degree of pigmentation was observed and judged according to the following criteria.

【0024】[判定基準] 炎症についての判定基準(抗炎症効果) 0:炎症がまったく認められない 1:ごく僅か炎症が認められる 2:炎症が認められるが、非照射部位との境界は不明瞭 3:炎症が認められ、非照射部位との境界は鮮明[Criteria] Criteria for inflammation (anti-inflammatory effect) 0: No inflammation is observed 1: Very slight inflammation is observed 2: Inflammation is observed, but the boundary with the non-irradiated area is unclear 3: Inflammation was observed, and the boundary with the non-irradiated area was clear

【0025】色素沈着についての判定基準(美白効果) 0:色素沈着がまったく認められない 1:ごく僅か色素沈着が認められる 2:色素沈着が認められるCriteria for pigmentation (whitening effect) 0: No pigmentation is observed 1: Very slight pigmentation is observed 2: Pigmentation is observed

【0026】(2)皮膚色明度回復試験法 被験者20名の背部皮膚にUV−B領域の紫外線を最小
紅斑量の2倍照射し、試料塗布部位と非塗布部位を設定
して各々の皮膚の基準明度(V0値,V0’値)を測定し
た。引き続いて塗布部位には試料を1日2回ずつ15週
間連続塗布した後、3,6,9,12,15週間後の塗
布部位及び非塗布部位の皮膚の明度(V n値,Vn’値)
を測定し、表1の判定基準に従って皮膚色の回復を評価
した。尚、皮膚の明度(マンセル表色系V値)は高速分
光色彩計で測定して得られたX,Y,Z値より算出し
た。また評価は被験者20名ついて、6週間後の評価点
の平均値で示した。
(2) Skin color lightness recovery test method Minimize UV rays in the UV-B region on the back skin of 20 subjects
Irradiate twice the amount of erythema and set the sample application area and non-application area
Then, the standard lightness (V0Value, V0’Value)
It was Subsequently, the sample was applied to the application site twice a day for 15 weeks.
After continuous application for 3,6,9,12,15 weeks
Lightness of skin (V and V) nValue, Vn'value)
And evaluate the recovery of skin color according to the criteria in Table 1.
did. The brightness of the skin (V value of Munsell color system) is high
Calculated from the X, Y, Z values obtained by measuring with a light colorimeter
It was In addition, the evaluation was made for 20 subjects and the evaluation points after 6 weeks
The average value of

【0027】[0027]

【表1】 [Table 1]

【0028】(3)官能試験 被験者20名が試料を10日間連用した後の試料の特性
を評価した。評価は、美白効果のアンケート項目に対
し、「美白効果が感じられた」と回答した人数で示し
た。
(3) Sensory test Twenty test subjects evaluated the characteristics of the sample after continuously using the sample for 10 days. The evaluation is shown by the number of respondents who answered "a whitening effect was felt" in the whitening effect questionnaire item.

【0029】実施例1〜5,比較例1〜4(抗炎症試
験) オトギリソウ抽出物とオリーブ葉抽出物を含有する化粧
水を表2の組成に基き、常法によって調製し、前記の試
験(1)を実施した。その結果を表2に併せて示す。本
発明の実施例1〜5の化粧水は、抗炎症効果及び美白効
果において良好な結果を示した。一方、比較例1〜4の
化粧水は、十分な効果が認められず、本発明の実施例に
比べて劣っていた。
Examples 1 to 5 and Comparative Examples 1 to 4 (Anti-inflammatory test) A lotion containing the Hypericum perforatum extract and the olive leaf extract was prepared according to the conventional method based on the composition shown in Table 2, and the above test ( 1) was carried out. The results are also shown in Table 2. The lotions of Examples 1 to 5 of the present invention showed good results in anti-inflammatory effect and whitening effect. On the other hand, the lotions of Comparative Examples 1 to 4 were inferior to the examples of the present invention, because no sufficient effect was observed.

【0030】[0030]

【表2】 [Table 2]

【0031】実施例6〜9,比較例5〜8 オトギリソウ抽出物とオリーブ葉抽出物とを含有するス
キンクリームを表3、4の組成に基き、常法によって調
製した。これらを試料として前記の試験(2)、(3)
を実施した。その結果を表4に併せて示す。
Examples 6 to 9 and Comparative Examples 5 to 8 Skin creams containing Hypericum perforatum extract and olive leaf extract were prepared by a conventional method based on the compositions shown in Tables 3 and 4. The above tests (2) and (3) using these as samples
Was carried out. The results are also shown in Table 4.

【0032】[0032]

【表3】 [Table 3]

【0033】[0033]

【表4】 [Table 4]

【0034】本発明の実施例6〜9のスキンクリーム
は、前記諸試験において良好な結果を示した。一方、比
較例5〜8のスキンクリームは、十分な効果が認められ
ず、本発明の実施例に比べて劣っていた。
The skin creams of Examples 6 to 9 of the present invention showed good results in the above tests. On the other hand, the skin creams of Comparative Examples 5 to 8 were inferior to those of the examples of the present invention because sufficient effects were not recognized.

【0035】実施例10(スキンローション) 下記の組成のスキンローションを常法に従い調製した。
尚、香料は表5記載の組成のものを用いた。
Example 10 (skin lotion) A skin lotion having the following composition was prepared by a conventional method.
The fragrance used had the composition shown in Table 5.

【0036】 配合成分 配合量(質量%) エタノール 8.0 モノラウリン酸ポリオキシエチレンソルビタン(20E.O.) 0.4 メチルパラベン 0.1 香料 0.01 1,3−ブチレングリコール 3.0 ポリエチレングリコール1000 0.3 オトギリソウ抽出物 0.5 オリーブ葉抽出物 0.5 精製水 87.19[0036] Blending ingredients Blending amount (mass%) Ethanol 8.0 Polyoxyethylene sorbitan monolaurate (20EO) 0.4 Methylparaben 0.1 Fragrance 0.01 1,3-butylene glycol 3.0 Polyethylene glycol 1000 0.3 Hypericum extract 0.5 Olive leaf extract 0.5 Purified water 87.19

【0037】この実施例10のスキンローションは前記
諸試験において良好な結果を示した。
The skin lotion of this Example 10 showed good results in the above tests.

【0038】実施例11(デイエッセンス) 下記の組成のデイエッセンス(日中用美容液)を常法に
従い調製した。尚、香料は表5記載の組成のものを用い
た。
Example 11 (day essence) A day essence (daytime beauty essence) having the following composition was prepared by a conventional method. The fragrance used had the composition shown in Table 5.

【0039】 配合成分 配合量(質量%) (A)成分 ステアリン酸 0.5 親油型モノステアリン酸グリセリン 1.0 メチルフェニルポリシロキサン 3.0 パラソルMCX * 5.0 パラソル1789 ** 2.0 流動パラフィン 2.0 香料 0.05 (B)成分 N−ステアロイル−L−グルタミン酸ナトリウム 0.5 グリセリン 5.0 オトギリソウ抽出物 0.3 オリーブ葉抽出物 0.5 アラントイン 0.5 キサンタンガム 0.15 二酸化チタン 5.0 精製水 74.5 *,**:ジボダン社製[0039] Blending ingredients Blending amount (mass%) (A) component Stearic acid 0.5 Lipophilic type glyceryl monostearate 1.0 Methylphenyl polysiloxane 3.0 Parasol MCX * 5.0 Parasol 1789 ** 2.0 Liquid paraffin 2.0 Fragrance 0.05 (B) component N-stearoyl-L-glutamate sodium 0.5 Glycerin 5.0 Hypericum extract 0.3 Olive leaf extract 0.5 Allantoin 0.5 Xanthan gum 0.15 Titanium dioxide 5.0 Purified water 74.5 *, **: Made by Givaudan

【0040】この実施例11のデイエッセンスは前記諸
試験において良好な結果を示した。
The deessence of Example 11 showed good results in the above-mentioned tests.

【0041】[0041]

【表5】 [Table 5]

【0042】尚、いずれの実施例の組成物を使用した場
合にも、皮膚に炎症、その他副作用と考えられる症状は
発現せず、本発明に係る皮膚外用剤は安全性にも優れる
ことが明らかであった。
It should be noted that, when the compositions of any of the Examples are used, the skin does not exhibit inflammation or other symptoms considered to be side effects, and it is clear that the external preparation for skin according to the present invention is excellent in safety. Met.

【0043】[0043]

【発明の効果】以上記載のごとく、本発明は優れた皮膚
炎症防止効果、美白効果を有する皮膚外用剤を提供する
ことが明らかである。
EFFECTS OF THE INVENTION As described above, it is apparent that the present invention provides a skin external preparation having excellent skin inflammation prevention and whitening effects.

フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 7/00 A61K 7/00 W A61P 17/00 A61P 17/00 (72)発明者 高橋 慶人 神奈川県小田原市寿町5丁目3番28号 カ ネボウ株式会社基礎科学研究所内 (72)発明者 日下 あゆみ 神奈川県小田原市寿町5丁目3番28号 カ ネボウ株式会社基礎科学研究所内 Fターム(参考) 4C083 AA111 AA112 AB242 AC022 AC102 AC112 AC122 AC172 AC242 AC262 AC392 AC442 AC482 AC662 AC851 AC852 AD042 AD092 AD152 AD172 AD352 AD492 AD531 AD532 EE10 EE16 Front page continuation (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 7/00 A61K 7/00 W A61P 17/00 A61P 17/00 (72) Inventor Keito Takahashi Hisashi Odawara, Kanagawa Prefecture 5-3-28, Machi Kanebo Ltd., Institute of Basic Science (72) Inventor Ayumi Kusaka 5-3-28, Kotobukicho, Odawara-shi, Kanagawa F-Term, Kanebo Ltd., Institute of Basic Science (reference) 4C083 AA111 AA112 AB242 AC022 AC102 AC112 AC122 AC172 AC242 AC262 AC392 AC442 AC482 AC662 AC851 AC852 AD042 AD092 AD152 AD172 AD352 AD492 AD531 AD532 EE10 EE16

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】 オトギリソウから得られる抽出物、及び
オリーブの枝葉部から得られる抽出物を含有することを
特徴とする皮膚外用剤。
1. An external preparation for skin, comprising an extract obtained from Hypericum perforatum and an extract obtained from the branches and leaves of olives.
【請求項2】 更にグリチルリチン酸及びその誘導体、
グリチルレチン酸及びその誘導体、アラントインからな
る群より選択される1種又は2種以上を含有することを
特徴とする請求項1記載の皮膚外用剤。
2. Glycyrrhizic acid and its derivatives,
The external preparation for skin according to claim 1, which contains one or more selected from the group consisting of glycyrrhetinic acid and its derivatives and allantoin.
JP2001382687A 2001-12-17 2001-12-17 External preparation for skin Expired - Fee Related JP3574107B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001382687A JP3574107B2 (en) 2001-12-17 2001-12-17 External preparation for skin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001382687A JP3574107B2 (en) 2001-12-17 2001-12-17 External preparation for skin

Publications (2)

Publication Number Publication Date
JP2003183146A true JP2003183146A (en) 2003-07-03
JP3574107B2 JP3574107B2 (en) 2004-10-06

Family

ID=27592952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001382687A Expired - Fee Related JP3574107B2 (en) 2001-12-17 2001-12-17 External preparation for skin

Country Status (1)

Country Link
JP (1) JP3574107B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10732171B2 (en) 2011-12-20 2020-08-04 The Procter & Gamble Company Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10732171B2 (en) 2011-12-20 2020-08-04 The Procter & Gamble Company Human skin sample methods and models for validating hypotheses for mechanisms driving skin pigmentation

Also Published As

Publication number Publication date
JP3574107B2 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
JP2890212B2 (en) Cosmetics
JP5047527B2 (en) Topical skin preparation
JP2009029734A (en) External preparation for skin
JP3480952B2 (en) External preparation for skin
JPH04346911A (en) Cosmetic
JPH06336421A (en) External agent for skin
JP2000038334A (en) Bleaching cosmetic containing resorcinol derivative
JP2896815B2 (en) Cosmetics
JP3010560B2 (en) Cosmetics
JP3574107B2 (en) External preparation for skin
JP6723979B2 (en) Wrinkle improver
JPH0640933A (en) Antiinflammatory agent
JPH04346912A (en) Cosmetic
JP3027409B2 (en) Cosmetics
JP2896816B2 (en) Cosmetics
JP4037836B2 (en) Hyaluronidase activity inhibitor
JP2896814B2 (en) Cosmetics
JP2811479B2 (en) Hair restoration
JP2007302704A (en) External preparation for skin and skin-bleaching agent
JP2004323467A (en) Skin care preparation for external use
JP2004137166A (en) Skin care preparation for external use, cell activator and antioxidant
JP4473439B2 (en) Whitening agent
JP2004010757A (en) Antioxidant
WO2021133307A1 (en) Cosmetic formulation containing the smoke tree extract
JPH05320034A (en) Cosmetic

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040310

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040421

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040528

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040629

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040630

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 3574107

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090709

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100709

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110709

Year of fee payment: 7

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110709

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120709

Year of fee payment: 8

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120709

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130709

Year of fee payment: 9

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees